2000
DOI: 10.1016/s1462-9011(00)00025-3
|View full text |Cite
|
Sign up to set email alerts
|

What is ‘normative’ at cooling water intakes? Defining normalcy before judging adverse

Abstract: Judgments of adverse environmental impact from cooling water intake structures need to be preceded by an appreciation of what is normal. In its report, Return tu the River, the Independent Scientific Group (now called the Independent Scientific Advisory Board)--the scientific peer review arm of the Northwest Power Planning Council--advanced the notion of a "normative river ecosystem" as a new conceptual foundation for salmonid recovery in the Columbia River basin. With this perspective, the sum of the best sci… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2001
2001
2010
2010

Publication Types

Select...
3
1
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 6 publications
0
1
0
Order By: Relevance
“…Jasanoff (1990), in her case studies, provided numerous examples. This includes the choice of theoretical models in evaluating exposure pathways/harm mechanism, the preferred observation methods, the scientific models on dose-effect relationship, the subjectivity involved in counting excess tumors, the appropriate extrapolation factor from animal test to humans and the judgment involved in deciding whether observed effects in one tissue is idiosyncratic or can be generalized (for additional examples of how science and policy are socially negotiated, see Coutant (2000)). Since the research design, the chosen paradigms for ana-lyzing clinical trials results, the acceptable level of harm and what is deemed as acceptable proof are all subject to social negotiation, this suggests that the "science" behind FDA's science policy is malleable (Jasanoff, 1990).…”
Section: Regulatory Dependencementioning
confidence: 99%
“…Jasanoff (1990), in her case studies, provided numerous examples. This includes the choice of theoretical models in evaluating exposure pathways/harm mechanism, the preferred observation methods, the scientific models on dose-effect relationship, the subjectivity involved in counting excess tumors, the appropriate extrapolation factor from animal test to humans and the judgment involved in deciding whether observed effects in one tissue is idiosyncratic or can be generalized (for additional examples of how science and policy are socially negotiated, see Coutant (2000)). Since the research design, the chosen paradigms for ana-lyzing clinical trials results, the acceptable level of harm and what is deemed as acceptable proof are all subject to social negotiation, this suggests that the "science" behind FDA's science policy is malleable (Jasanoff, 1990).…”
Section: Regulatory Dependencementioning
confidence: 99%